Encouraging studies! 🧵
An analysis of cross-reactive viral binding and neutralization of emerging SARS-CoV-2 variants shows Novavax’s and Moderna’s vaccines elicit immune responses that are effective against variants B.1.429 (CA) and B.1.351 (S. Africa). nejm.org/doi/full/10.10…
Patients previously infected with SARS-CoV-2 received Pfizer’s vaccine. Before vaccination, they had neutralizing activity against variants B.1.1.7 & P.1 but not B.1.351. AFTER one dose, neutralizing activity against ALL variants increased substantially! nejm.org/doi/full/10.10…
Convalescent serum from those who recovered from an infection with SARS-CoV-2 variant B.1.351 showed potent neutralization of D614G (original), as well as variants B.1.351 (S. Africa) AND P.1 (Brazil). Booster vaccines may just seal the deal if needed! nejm.org/doi/full/10.10…
3 weeks after a single dose, those with recent SARS-CoV-2 infection or seropositive status had higher levels of antibody to 4 SARS-CoV-2 antigens and higher levels of antibodies with neutralizing characteristics than those without a history of infection. nejm.org/doi/full/10.10…
Moderna’s vaccine significantly reduces neutralizing activity against VOCs B.1.1.7 (UK), B.1.1.7+ E484K, P.1 (Brazil), B.1.351 (S. Africa) AND B.1.427/B.1.429 (CA). nejm.org/doi/full/10.10…
Data from a UK clinical study suggests the AstraZenecas vaccine is 70.4% effective against symptomatic COVID-19 caused by variant B.1.1.7. The vaccine was 81.5% effective in preventing symptomatic COVID-19 caused by non-B.1.1.7 strains. thelancet.com/journals/lance…
Antibody titers of vaccinees who recovered from a previous SARS-CoV-2 infection were found to be 10x to 45x as high as those of vaccinees without preexisting immunity at the same time points after just one dose of either mRNA vaccine. nejm.org/doi/full/10.10…
Serum samples obtained from participants vaccinated with two doses of Pfizer’s BNT162b2 COVID-19 vaccine shows effective neutralization against VOCs B.1.1.7 (UK), B.1.351 (S. Africa) AND P.1 (Brazil). nejm.org/doi/full/10.10…
Why is this all good news? Because the vaccines are effective! This thread includes something on just about each of them. These also don’t even take into account cell-mediated immunity/ my love of T-cells which add a whole other layer of protection!
Have a great day! ☀️🧬🦠🧫💉
• • •
Missing some Tweet in this thread? You can try to
force a refresh
All immunity is natural, because your immune system is natural.
It is acquired either through infection or vaccination. Infection has more side effects, many of which are very bad and one of which is death.
Naturally, I choose to acquire my immunity through vaccination.
As originally stated by Dr. Rasmussen. I won’t tag her fully only because I don’t want to needlessly flood her mentions. I thought this was one of THE most influential statements regarding vaccination and immunity and that is why I wanted to share it today.
Recently, I have been getting a fair amount of questions regarding updated vaccines that are AVAILABLE NOW, timing, and current circulating SARS-CoV-2 strains so I figured an UPDATED thread would be helpful! 🧪🧵⬇️
So, not COVID related BUT, this is REALLY exciting news. Interim data shows Moderna’s solid tumor vaccine candidate mRNA-4359, has shown early signs of efficacy AND activated key proteins to trigger an immune response for cancer killing cells.
Let’s talk about that! 🧵⬇️
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), has shown promise in patients with advanced solid cancers.
This investigational mRNA cancer immunotherapy is targeted for patients with lung cancer, melanoma and other solid tumors.
Nineteen patients with advanced stage cancers received between one and nine doses of mRNA-4359. Researchers found the immunotherapy created an immune response against cancer and was well tolerated, with adverse events including fatigue, injection site pain and fever.
THIS IS HUGE! Researchers at The University of Texas at Austin have discovered and isolated a broadly neutralizing plasma antibody, known as SC27, which has been shown to neutralize ALL known variants of SARS-CoV-2.
Researchers say a newly discovered antibody could pave the way for vaccines or treatments that provide universal protection against all SARS-CoV-2 variants, along with other related viruses.
Researchers at UT Austin and several other universities collaborated on this new study
Here Is All You NEED TO KNOW About The Updated COVID-19 Shots Available NEXT WEEK!
Thank You For Reading! 🧵⬇️
🎨: @JJENIAC
Recently, I have been getting a fair amount of questions regarding updated vaccines, timing, and current circulating SARS-CoV-2 strains so I figured an UPDATED thread would be helpful!
The FDA has approved and authorized UPDATED mRNA COVID-19 Vaccines. Novavax is still PENDING. The shots are formulated to target the "FLiRT" variants. KP.3 was identified this spring and has become the top variant since. This variant is part of the “FLiRT” family
Reminder. We DO have a vaccine for Mpox. It’s the Smallpox vaccine, which successfully eradicated a disease that killed more than 300 million people since 1900. A massive global vaccination campaign put an end to that disease in 1977. Please stop the misinformation.🧵⬇️
IMPORTANT NOTE. JYNNEOS (Imvanex, IMVAMUNE) is a non-replicating vaccine for smallpox that CAN BE USED SAFELY in immunocompromised individuals and individuals with skin conditions such as eczema against Mpox.
•
• precisionvaccinations.com/vaccines/jynne… cdc.gov/poxvirus/mpox/…
Mpox IS NOT NEW. It is an emerging zoonotic disease and is actually endemic in parts of Africa. Unfortunately, some individuals are behaving as if it has just been “discovered.” Mpox has been declared a PHEIC again due to an upsurge in cases IN and NEAR the DRC. PLEASE NOTE:
THIS IS HUGE! A new nasal COVID-19 vaccine BLOCKS transmission of the virus, according to a recent study out of Washington University. This suggests vaccines delivered directly to the nose or mouth could play a critical role in containing the spread of respiratory infections.🧵⬇️
A new study by researchers at Washington University School of Medicine in St. Louis indicates that next-generation vaccines that target the virus’s points of entry- the nose and mouth- may be able to do what traditional shots cannot: contain the spread of respiratory infections